Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102No adverse events attributed to ...

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance ...
MedPage Today on MSN

FDA Approves At-Home Starter Dose of Alzheimer's Drug

Lecanemab decision marks first time patients can begin treatment with home administration ...
The American Journal of Managed Care

FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease

Once-weekly 500 mg subcutaneous initiation is delivered by autoinjector as two 250 mg injections, allowing self- or caregiver administration at home rather than clinic-based IV starts. FDA acceptance ...
Medscape

FDA Okays At-Home Starting Dose for Lecanemab in Early AD

The most common side effects of IV lecanemab are headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of an ...
Medscape

FDA Approves Subcutaneous Isatuximab for Multiple Myeloma Indications

The FDA has approved a subcutaneous version of isatuximab (Sarclisa Escena, Sanofi-Aventis) for several multiple myeloma (MM) ...
TMCnet

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association ...

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International Conference ® (AAIC ®) 2026 in London support that the LEQEMBI ® ...
Drug Store News

Sandoz offers generic Remodulin for subcutaneous administration

Sandoz is offering treprostinil injection for subcutaneous administration to treat patients diagnosed with pulmonary arterial hypertension. Sandoz treprostinil injection was the first generic of ...
FiercePharma

FDA Approves Subcutaneous Administration of VELCADE In All Approved Indications

- Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy - CAMBRIDGE, Mass., January 23, 2012-Millennium: The Takeda Oncology Company with ...
Nature

Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers

The gastric hormone ghrelin appears a useful agent to stimulate food intake in people with anorexia of illness. The loss of ghrelin's acyl group renders it inactive, thus it has been thought that ...

FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a ...
PharmaTimes

FDA approves Leqembi Iqlik subcutaneous initiation dose for Alzheimer’s disease

Eisai and Biogen have announced that the U.S. Food and Drug Administration has approved a supplemental biologics licence application for a once weekly subcutaneous initiation dose ...